Stocksigma LogoStocksigma Logo

Medicamen Organics Reports H1 FY27 Results and Preferential Fundraise Utilisation

Medicamen Organics reported consolidated revenue from operations of ₹699.05 Lakhs for the half-year ended 30th Sep'26, down YoY from ₹1,785.23 Lakhs, with

Medicamen Organics Reports H1 FY27 Results and Preferential Fundraise Utilisation

Medicamen Organics Ltd · Outcome · 16 Nov 2026, 8:33 pm

Medicamen Organics Reports H1 FY27 Results and Preferential Fundraise Utilisation Medicamen Organics reported consolidated revenue from operations of ₹699.05 Lakhs for the half-year ended 30th Sep'26, down YoY from ₹1,785.23 Lakhs, with a net loss of ₹414.78 Lakhs versus a profit of ₹203.80 Lakhs in H1 FY26. Standalone revenue fell to ₹567.26 Lakhs, posting a net loss of ₹405.46 Lakhs. The company completed a ₹9.50 Cr preferential allotment and raised ₹12.29 Cr across equity and warrants, utilizing ₹10.92 Cr primarily for working capital without deviations. Auditor notes highlighted GST demands totaling ₹202.47 Lakhs and unreviewed Rwandan subsidiary financials.

Original exchange filing (PDF)

More announcements from Medicamen Organics Ltd

All Medicamen Organics Ltd announcements